Duavive
·
- Prescription status not stated
- Urinary and reproductive system, hormones
- Active substance
- Oestrogens conjugated;bazedoxifene
- Made by
- Pfizer Europe MA EEIG
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Duavive is indicated for: Treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-containing therapy is not appropriate. The experience treating women older than 65 years is limited.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | Pfizer Europe MA EEIG |
|---|---|
| Active substance | Oestrogens conjugated;bazedoxifene |
| Used in | Urinary and reproductive system, hormones |
| Classification | G03CC07 · Urinary and reproductive system, hormones |
| Authorised on | 2014-12-16 |
| Last updated by the regulator | 2025-11-06 |
| EMA product number | EMEA/H/C/002314 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).